Assertio

OverviewSuggest Edit

Assertio (formerly Depomed) is a specialty pharmaceutical company focused on developing and commercializing products to treat pain and other central nervous system conditions. It offers INDOCIN, a non-steroidal anti-inflammatory drug, and CAMBIA, a prescription medicine used to treat migraine attacks. In addition, the company provides ZIPSOR, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults, and SPRIX, a solution for the management of moderate to moderately severe pain that requires analgesia at the opioid level.

TypePublic
Founded1995
HQLake Forest, IL, USMap
Websiteassertiotx.com
Employee Ratings3.5More

Recent NewsAll News

Latest Updates

Employees (est.) (Mar 2021)27(-78%)
Revenue (FY, 2020)$106.3 M(-53%)
Share Price (Sept 2021)$1(-3%)
Cybersecurity ratingAMore

Key People/Management at Assertio

Dan A. Peisert

Dan A. Peisert

President, Chief Executive Officer & Director
Jeff Christensen

Jeff Christensen

Senior Vice President, Commercial
Jack Hoblitzell

Jack Hoblitzell

Senior Vice President, Technical Operations
Sam Schlessinger

Sam Schlessinger

Vice President, Legal
Ajay Patel

Ajay Patel

Senior Vice President, Chief Accounting Officer
Paul Schwichtenberg

Paul Schwichtenberg

Senior Vice President, Chief Financial Officer
Show more

Assertio Office Locations

Assertio has an office in Lake Forest
Lake Forest, IL, US (HQ)
100 S Saunders Rd Ste 300
Show all (1)

Assertio Financials and Metrics

Assertio Revenue

Embed Graph
View revenue for all periods
Assertio's revenue was reported to be $106.28 m in FY, 2020 which is a 53.7% decrease from the previous period.
USD

Revenue (Q2, 2021)

24.8m

Market capitalization (9-Sept-2021)

42.7m

Closing stock price (9-Sept-2021)

1.0

Cash (30-Jun-2021)

54.4m

EV

67.2m
Assertio's current market capitalization is $42.7 m.
Annual
USDFY, 2018FY, 2019FY, 2020

Revenue

311.8m229.5m106.3m

Revenue growth, %

(18%)(26%)(54%)

Cost of goods sold

18.5m9.5m19.9m

Gross profit

293.3m220.0m86.4m
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021

Revenue

128.4m63.3m77.5m57.9m57.2m55.1m20.9m20.6m34.3m26.8m24.8m

Cost of goods sold

12.0m2.8m3.0m2.6m2.1m2.2m1.4m5.2m6.5m4.0m

Gross profit

116.4m60.5m74.5m55.4m55.1m52.9m19.5m15.4m27.8m22.9m

Gross profit Margin, %

91%96%96%96%96%96%93%75%81%85%
show all
Annual
USDFY, 2018FY, 2019FY, 2020

Cash

110.9m42.1m20.8m

Accounts Receivable

37.2m42.7m44.4m

Prepaid Expenses

56.6m15.7m17.4m

Inventories

3.4m3.4m11.7m
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021

Cash

101.7m57.2m121.9m109.7m68.3m54.2m106.0m59.4m34.7m61.0m54.4m

Accounts Receivable

62.4m42.1m43.9m43.5m34.3m43.4m13.0m34.8m39.2m39.2m45.5m

Prepaid Expenses

23.8m22.7m57.3m25.7m26.2m23.5m10.7m15.9m17.1m14.9m12.8m

Inventories

5.4m5.0m4.3m3.1m3.0m3.3m518.0k25.4m13.5m8.9m6.6m
show all
Annual
USDFY, 2018FY, 2019FY, 2020

Net Income

36.9m(217.2m)(28.1m)

Depreciation and Amortization

106.4m102.9m26.4m

Inventories

9.0m(316.0k)(291.0k)

Accounts Payable

(33.6m)(15.1m)(28.6m)
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021

Net Income

33.8m12.8m61.0m(14.3m)(27.9m)(24.6m)41.2m6.7m(3.8m)4.5m(9.6m)

Depreciation and Amortization

26.9m53.8m80.7m26.0m51.5m77.2m8.1m13.3m19.5m6.8m14.3m

Inventories

7.5m7.8m8.5m(40.0k)195.0k(213.0k)(2.4m)512.0k(792.0k)2.6m5.0m

Accounts Payable

(33.5m)(44.3m)(28.1m)(12.4m)(14.9m)17.4m(10.5m)(13.3m)(18.4m)(16.7m)(3.9m)
show all
USDQ1, 2018

Revenue/Employee

755.3k

Debt/Equity

3.1 x

Debt/Assets

0.6 x

Financial Leverage

4.9 x
Show all financial metrics

Assertio Operating Metrics

FY, 2018FY, 2019FY, 2020May, 2021

Patents (US)

232312

Products

758

Trademarks

15
Show all operating metrics

Assertio Acquisitions / Subsidiaries

Company NameDateDeal Size
Zyla Life SciencesMarch 20, 2020
Nautilus NeurosciencesDecember 17, 2013
Alligator IP, LLC
Assertio Distribution, LLC
Assertio Management, LLC
Assertio Therapeutics, Inc.
Depo DR Sub, LLC
Depo NF Sub, LLC
Egalet Limited
Zyla Life Sciences, Inc.
Show more

Assertio Revenue Breakdown

Embed Graph

Assertio revenue breakdown by business segment: 29.8% from INDOCIN Products, 26.7% from CAMBIA, 12.5% from Zipsor, 10.4% from SPRIX, 10.6% from Commercialization agreement revenue and 10.0% from Other

Assertio Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

Learn more about our premium products
SecurityScorecard logo

Assertio Online and Social Media Presence

Assertio's Trends

Embed Graph

Assertio News and Updates

July 20, 2021

Assertio Holdings, Inc. to Report Second Quarter 2021 Financial Results After the Close of Markets on Thursday, August 5, 2021

LAKE FOREST, Ill., July 20, 2021 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) today announced that it will release second quarter 2021 financial results on Thursday, August 5, 2021, after the close of markets. Following the release of its financial resul…
June 04, 2021

Assertio Holdings, Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement

LAKE FOREST, Ill., June 04, 2021 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) today announced that that it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (the “Nasdaq”) indicating that the Company…
May 07, 2021

Bausch, Assertio, Lupin must face antitrust claims over diabetes drug Glumetza

Bausch Health Cos Inc, Assertio Therapeutics Inc and Lupin Pharmaceuticals Inc must face claims by purchasers of Bausch's type 2 diabetes drug Glumetza that they conspired to suppress generic competition through an illegal patent settlement, enabling an 800% price hike in 2015, a federal judge has r…
May 06, 2021

Assertio Reports First Quarter 2021 Financial Results

Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a leading commercial pharmaceutical company bringing differentiated products to patients, today reported financial results for the first quarter ended March 31, 2021.
May 05, 2021

Assertio Holdings, Inc. Partners With Cove, a Leading Migraine Telemedicine Platform, to Launch Direct to Patient Digital Campaign to Increase Accessibility of Cambia® (Diclofenac Potassium) and Sprix® (Ketorolac Tromethamine)

Assertio Holdings, Inc. (“Assertio” or “the Company”) (NASDAQ: ASRT), and Cove, a leading migraine telemedicine platform, today announced a collaboration to make CAMBIA (diclofenac potassium) for oral solution and SPRIX (ketorolac tromethamine) nasal spray available to Cove’s patient population. Thi…
April 22, 2021

Assertio Holdings, Inc. to Report First Quarter 2021 Financial Results After the Close of Markets on Thursday, May 6, 2021

Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) today announced that it will release first quarter 2021 financial results on Thursday, May 6, 2021, after the close of markets. Following the release of its financial results, Assertio’s management will host a conference call begin…
Show more

Assertio Blogs

October 08, 2018

Assertio Therapeutics to Report Third-Quarter 2018 Financial Results After The Close of Markets on Thursday, November 8, 2018

LAKE FOREST, Ill. , Oct. 08, 2018 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ:ASRT) today announced that it will release third-quarter 2018 financial results on Thursday, November 8, 2018 , after the close of markets. Following the announcement, the Company will host a conference call
August 09, 2018

Depomed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Depomed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Content Import Wed, 08/08/2018 - 22:37 Depomed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) July 6, 2018 at 4:05 PM EDT This release is a backfill from a News Wire …
August 09, 2018

Depomed to Report Second-Quarter 2018 Financial Results on Wednesday, August 8, 2018

Depomed to Report Second-Quarter 2018 Financial Results on Wednesday, August 8, 2018 Content Import Wed, 08/08/2018 - 22:37 Depomed to Report Second-Quarter 2018 Financial Results on Wednesday, August 8, 2018 July 9, 2018 at 8:31 AM EDT This release is a backf…
August 09, 2018

Depomed Announces NUCYNTA® Commercialization Agreement with Collegium Pharmaceutical

Depomed Announces NUCYNTA® Commercialization Agreement with Collegium Pharmaceutical Content Import Wed, 08/08/2018 - 22:37 Depomed Announces NUCYNTA® Commercialization Agreement with Collegium Pharmaceutical December 4, 2017 at 4:31 PM EST This release is a b…
July 27, 2018

Arthur J. Higgins

Arthur J. Higgins deborah.drisco… Thu, 07/26/2018 - 23:10 Arthur J. Higgins

 Assertio Frequently Asked Questions

  • When was Assertio founded?

    Assertio was founded in 1995.

  • Who are Assertio key executives?

    Assertio's key executives are Dan A. Peisert, Jeff Christensen and Jack Hoblitzell.

  • How many employees does Assertio have?

    Assertio has 27 employees.

  • What is Assertio revenue?

    Latest Assertio annual revenue is $106.3 m.

  • What is Assertio revenue per employee?

    Latest Assertio revenue per employee is $3.9 m.

  • Who are Assertio competitors?

    Competitors of Assertio include JanOne, iNova Pharmaceuticals and Purdue Pharma.

  • Where is Assertio headquarters?

    Assertio headquarters is located at 100 S Saunders Rd Ste 300, Lake Forest.

  • Where are Assertio offices?

    Assertio has an office in Lake Forest.

  • How many offices does Assertio have?

    Assertio has 1 office.